Chalcogen Attached Indirectly To The Six-membered Hetero Ring By Nonionic Bonding (e.g., Sulfato Betaines, Etc.) Patents (Class 546/339)
  • Patent number: 10017490
    Abstract: An object of the present invention is to provide a novel endoparasite control agent as a parasiticide, an antiprotozoal or the like. Provided is an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I): or a salt thereof as an active ingredient.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: July 10, 2018
    Assignees: The University of Tokyo, Nihon Nohyaku Co., Ltd.
    Inventors: Kiyoshi Kita, Akiyuki Suwa, Masatsugu Oda, Koji Tanaka
  • Patent number: 9850261
    Abstract: Compositions and methods using silicon-based cross-coupling agents in the formation of carbon-carbon and carbon-nitrogen bonds are described.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: December 26, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Adam T. Hoye, Won-Suk Kim, Dionicio Martinez-Solorio, Amos B. Smith, III, Rongbiao Tong, Minh Huu Nguyen, Luis Sanchez, Bruno Nicolas Melillo
  • Patent number: 9573901
    Abstract: The present invention belongs to the field of pharmaceutical chemistry, and disclosed are two crystal forms of Childamide, that is, Chidamide crystal form A and Chidamide crystal form B, and the method for preparing the new crystal forms of Chidamide. The Chidamide crystal form A and Chidamide crystal form B of the present invention can be used for preparing drugs for treating diseases related to cell differentiation and proliferation.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: February 21, 2017
    Assignee: SHENZHEN CHIPSCREEN BIOSCIENCES, LTD.
    Inventors: Xianping Lu, Zhibin Li
  • Patent number: 9434691
    Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: September 6, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
  • Patent number: 9358224
    Abstract: Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: June 7, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Elena Losi, Enrico Zambelli
  • Patent number: 9040538
    Abstract: The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: May 26, 2015
    Assignee: Universite Laval
    Inventors: Giorgio Attardo, Sasmita Tripathy, Martin Gagnon
  • Patent number: 9023874
    Abstract: The invention relates to alkylsulfide derivatives compounds of formula I as hereunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to methods for controlling invertebrate pests by using these compounds and to plant propagation material and to agricultural and veterinary compositions comprising said compounds. wherein U, R1, R2, R3U, X, n and p are defined as in the description.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: May 5, 2015
    Assignee: Merial, Inc.
    Inventors: Sebastian Soergel, Ralph Paulini, Steffen Gross, Carsten Beyer, Matthias Pohlman, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Douglas D. Anspaugh, Sarah Thompson, Vincent Salgado
  • Publication number: 20150087833
    Abstract: An alkyl phenyl sulfide derivative represented by the general formula [I] or an agriculturally acceptable salt thereof, and a pest control agent containing the derivative or the salt as an active ingredient. [in the above formula, R1 is, for example, a C1˜C6 alkyl group which is mono- or poly-substituted with halogen atom; R2 is, for example, a halogen atom or a C1˜C6 alkyl group; R3 is, for example, a hydrogen atom or a halogen atom; and R4 is, for example, a hydrogen atom or a C1˜C12 alkyl group.] The derivative or the salt has an excellent pest control effect.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 26, 2015
    Applicants: IHARA CHEMICAL INDUSTRY CO., LTD., KUMIAI CHEMICAL INDUSTRY CO., LTD.
    Inventors: Kei Domon, Keiji Toriyabe, Yutaka Ogawa, Junichiro Bessho, Kei Kawamoto, Akira Watanabe, Masaaki Komatsu, Takeshi Matsuda, Seisuke Ito
  • Publication number: 20150060732
    Abstract: An object is to provide a liquid crystal compound satisfying at least one of physical properties such as a high stability to heat and light, a high clearing point, a low minimum temperature of a liquid crystal phase, a small viscosity, a suitable optical anisotropy, a large dielectric anisotropy, a suitable elastic constant and an excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. A solution is a compound represented by formula (1). In formula 1, R1 is alkyl having 1 to 10 carbons, for example; ring A1 and ring A2 are independently 1,4-cyclohexylene or 1,4-phenylene; Z1 and Z2 are independently a single bond or —CF2O—; L1 and L2 are halogen; and a is 1 or 2.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Applicants: JNC PETROCHEMICAL CORPORATION, JNC CORPORATION
    Inventors: Yasuyuki GOTOH, Masakazu YANO
  • Publication number: 20150057449
    Abstract: One embodiment of the invention provides polyisobutylene (PIB) oligormers that are end-functionalized with ruthenium (Ru) catalysts. Such nonpolar catalysts can be dissolved in nonpolar solvents such as heptane, or any other nonpolar solvent that is otherwise not latently biphasic (i.e., if two or more solvent components are present, they remain miscible with each other throughout the entire reaction process, from the addition of substrate through to the removal of product). Substrate that is dissolved in the nonpolar solvent with the catalyst is converted into product. The lower solubility of the product in the nonpolar solvent renders it easily removable, either by extraction with a more polar solvent or by applying physical means in cases where the product precipitates from the nonpolar solvent. In this manner the catalysts are recycled; since the catalysts remain in the nonpolar solvent, a new reaction can be initiated simply by dissolving fresh substrate into the nonpolar solvent.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 26, 2015
    Applicant: The Texas A&M University System
    Inventors: David E. Bergbreiter, Hassan S. Bazzi, Chayanant Hongfa
  • Patent number: 8962851
    Abstract: The present invention discloses one pot process for enantioselective synthesis of single enantiomers of substituted sulphoxides 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles or said compounds in an enantiomerically enriched form.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: February 24, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Daya Ram Pal
  • Publication number: 20140364586
    Abstract: Reagents and methods for functionalizing polypeptides with moieties (alkylene glycol) molecules and glycan groups are disclosed that are based on a functionalizing reagent which comprises a nitrogen containing heterocyclic aromatic ring having a vinyl substituent that is capable of reacting with one or more thiol groups that are naturally present, or have been introduced into, the polypeptide, for example by employing a thiol group of one or more cysteine residues. The functionalizing reagent is covalently linked to a poly(alkylene glycol) molecule, such as a polyethylene glycol (PEG) molecule, or a glycan group so that the reaction between the vinyl group and the thiol group in the polypeptide covalently links the polypeptide to the poly(alkylene glycol) molecule and/or the glycan group.
    Type: Application
    Filed: June 26, 2014
    Publication date: December 11, 2014
    Inventors: Andrew Graham WATTS, Terrence Kantner, Amanda Barbara MacKenzie
  • Patent number: 8889878
    Abstract: The present invention relates to halogen-substituted amide derivatives of the general formula (I) in which R1 to R6, Q1 to Q8, A, V, W, X, Y, n and m are each defined as described in the description—and to a process for preparation thereof and to the use thereof as insecticides and acaricides.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: November 18, 2014
    Assignee: Bayer CropScience AG
    Inventors: Markus Heil, Eike Kevin Heilmann, Alexander Sudau, Tobias Kapferer, Friedrich August Mühlthau, Peter Jeschke, Arnd Voerste, Ulrich Görgens, Klaus Raming, Ulrich Ebbinghaus-Kintscher, Mark Drewes, Martin Adamczewski, Angela Becker
  • Patent number: 8883037
    Abstract: Chiral liquid crystal compounds of the general formula (1): in which at least one of R1 and R2 is a chiral substituent, K may be a single bond or the same as K1-5 and K1-5 denote a six-membered ring system which rings may be at least partially unsaturated, wherein the number of atoms in these rings or ring systems between the two atoms forming a part of the link to the next ring, or to one of the substituents R1 and R2, does not differ by more than one if counted in the clockwise, and in the counter-clockwise sense, starting from the same atom in each case, X1-20 denote alkyl, or alkoxy, or fluorinated alkyl, or fluorinated alkoxy groups, or atom H, or halogen atoms, mixtures comprising such chiral liquid crystal compounds, and liquid crystal displays comprising such mixtures as active ingredients.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: November 11, 2014
    Assignee: Tetragon LC Chemie AG
    Inventors: Wolfgang Haase, Artsiom Lapanik
  • Publication number: 20140329746
    Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
    Type: Application
    Filed: July 16, 2014
    Publication date: November 6, 2014
    Inventors: Xianqi Kong, Xinfu Wu, Abderrahim Bouzide, Isabelle Valade, David Migneault, Francine Gervais, Daniel Delorme, Benoit Bachand, Mohamed Atfani, Sophie Levesque, Bita Samim
  • Patent number: 8840866
    Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: September 23, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung
  • Publication number: 20140228563
    Abstract: Cis and trans ruthenium complexes that can be used as catalysts for ring opening metathesis polymerisation (ROMP) are described. The complexes are generally square pyramidal in nature, having two anionic ligands X. Corresponding cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand are also described. Polymers such as polydicyclopentadiene (PDCPD) can be prepared using the catalysts.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 14, 2014
    Applicant: University Court of the University of St. Andrews
    Inventor: Catherine Cazin
  • Patent number: 8791161
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: July 29, 2014
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
  • Publication number: 20140203209
    Abstract: An object is to provide a liquid crystal compound satisfying at least one of physical properties such as a high stability to heat, light and so forth, a high clearing point, a low minimum temperature of a liquid crystal phase, a small viscosity, a suitable optical anisotropy, a large dielectric anisotropy, a suitable elastic constant and an excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. A solution is the compound represented by formula (1): wherein, in formula (1), for example, R1 is alkyl having 1 to 10 carbons; ring A1 and ring A2 are independently 1,4-cyclohexylene or 1,4-phenylene; Z1 and Z2 are independently a single bond or —CF2O—; L1 and L2 are halogen; and a is 1 or 2.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Applicants: JNC PETROCHEMICAL CORPORATION, JNC CORPORATION
    Inventors: Yasuyuki GOTOH, Kenji HIRATA
  • Patent number: 8785480
    Abstract: In one embodiment, processes for the preparation of certain functionalized pyridine N-oxides are provided. In one form, the functionalized pyridine N-oxides include 2-substituted-5-(1-alkylthio)alkyl-pyridine N-oxides. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: July 22, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Douglas C. Bland, Ronald Ross, Jr., Peter L. Johnson, Timothy C. Johnson
  • Publication number: 20140158934
    Abstract: The instant invention relates to mesogenic media comprising one or more compounds selected from the group of compounds of formulae M-I and M-II wherein the parameters are as specified in the text, preferably to mesogenic media showing a blue phase, preferably stabilised by a polymer, and their use in electro-optical light modulation elements and their respective use in displays, as well as to such devices.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 12, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Michael Wittek, Norihiko Tanaka, Mila Fischer, Matthias Bremer, Andreas Taugerbeck
  • Publication number: 20140155511
    Abstract: Sulfur chelated ruthenium compounds represented by the following formula: wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C1-C7 alkyl group or optionally substituted aryl; X1 and X2 each independently represent halogen; Y1 and Y2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 5, 2014
    Inventors: N. Gabriel LEMCOFF, Amos BEN-ASULY
  • Patent number: 8742125
    Abstract: 2-Trifluoromethyl-5-(1-substituted)alkylpyridines of formula (I) wherein R1 and R2 independently represent H, C1-C4 alkyl, or either of R1 or R2 taken together with R3 represent a 4- to 6-membered saturated ring, or R1 taken together with R2 represents a 3- to 6-membered saturated ring optionally substituted with an O or a N atom, R3 represents C1-C4 alkyl or R3 taken together with either of R1 or R2 represent a 4- to 6-membered saturated ring, and X represents CH2, O or S, are produced efficiently and in high yield from an 4-alkoxy-1,1,1-trifluorobut-3-en-2-one (II) wherein R represents a C1-C4 alkyl by condensation with an enamine (III) wherein R1, R2, R3 and X are as previously defined, and R4 and R5 independently represent C1-C8 alkyl, C2-C8 alkenyl, C1-C8 arylalkyl, C1-C8 haloalkyl, C1-C8 alkoxyalkyl, C1-C8 alkylaminoalkyl, aryl or heteroaryl or R4 and R5 taken together with N represent a 5- or 6-membered saturated or unsaturated ring, to provide an intermediate of the formu
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: June 3, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary Alan Roth, Douglas C. Bland, James R. McConnell
  • Publication number: 20140142319
    Abstract: An efficient and highly Markovnikov selective organoactinide-, organolanthanide-, and organozirconium-catalyzed addition of aryl, benzyl, and aliphatic thiols to terminal alkynes is described. The corresponding vinyl sulfides are produced with little or no side-products.
    Type: Application
    Filed: December 16, 2013
    Publication date: May 22, 2014
    Applicant: Northwestern University
    Inventors: Tobin J. Marks, Charles J. Weiss, Stephen D. Wobser
  • Patent number: 8674110
    Abstract: The present invention relates to novel pyridylacetylene derivatives of formula I their preparation, their use as radio-traces/markers and compositions containing them.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: March 18, 2014
    Assignee: Novartis AG
    Inventors: Fabrizio Gasparini, Yves Auberson, Lea Kessler, Simon Mensah Ametamey
  • Patent number: 8629280
    Abstract: The present invention provides a method of producing oligomers of olefins, comprising reacting olefins with a catalyst under oligomerization conditions. The catalyst can be the product of the combination of a chromium compound and a pyridyl ether compound. In particular embodiments, the catalyst compound can be used to trimerize or tetramerize ethylene to 1-hexene, 1-octene, or mixtures of 1-hexene and 1-octene.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: January 14, 2014
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Lily J. Ackerman, Gary Michael Diamond, Keith Anthony Hall, James M. Longmire, Vince J. Murphy, Dawn E. Verdugo
  • Publication number: 20140012004
    Abstract: The invention relates to palladium(0) tris{tri-[3,5-bis(trifluoromethyl)-phenyl]-phosphine} complex of formula (I), as well as to its preparation and use. This compound is outstandingly stable, and can be used as catalyst with excellent results.
    Type: Application
    Filed: December 13, 2011
    Publication date: January 9, 2014
    Applicant: H4SEP KFT
    Inventors: Zoltán Daliczek, Tibor Soós, Zoltán Finta, Géza Timári, Gábor Vlád
  • Patent number: 8623942
    Abstract: The present invention provides a liquid curable epoxy resin composition that has excellent storage stability and curing properties and provides a cured product having excellent properties, particularly, excellent organic solvent resistance. For that purpose, a clathrate containing a carboxylic acid compound and at least one selected from the group consisting of an imidazole compound represented by formula (I), wherein R1 to R4 each represent a hydrogen atom or the like, and 1,8-diazabicyclo[5.4.0]undecene-7 (DBU) is mixed in an epoxy resin. The liquid curable epoxy resin composition uses a liquid epoxy resin or an organic solvent.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: January 7, 2014
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Masami Kaneko, Kazuo Ono, Natsuki Amanokura, Naoyuki Kamegaya
  • Publication number: 20130327251
    Abstract: Novel tridentate-, bidentate-, and monodentate-based aromatic adsorbates including self-assembled monolayers (SAMs), especially, mixed multi-component SAMs, where the adsorbates comprise an aromatic ring including one head group or a plurality of dentate head groups and one tunable tail group or a plurality of tail groups and methods for making the same, and methods for using same, their use in the preparation of homogeneously mixed multi-component self-assembled monolayers (SAMs). The adsorbants and SAMs derived therefrom are ideally suited for biosensing, biosensing diagnostics, biological interfacial mimics, surface protections for nanoparticles, inert coatings for artificial implants, and corrosion-resistant coatings for microelectronics components.
    Type: Application
    Filed: March 7, 2013
    Publication date: December 12, 2013
    Applicant: THE UNIVERSITY OF HOUSTON SYSTEM
    Inventors: T. Randall Lee, Supachai Rittikulsittichai, Thomas Frank, Burapol Singhana
  • Publication number: 20130303526
    Abstract: The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: September 16, 2011
    Publication date: November 14, 2013
    Applicant: Purdue Pharma L.P.
    Inventors: Chiyou NI, Bin Shao, Laykea Tafesse, Jiangchao Yao, Jianming Yu, Xiaoming Zhou
  • Patent number: 8580142
    Abstract: The invention provides a liquid crystal compound having stability to heat, light and so forth, a wide temperature range of a nematic phase, a small viscosity, a suitable optical anisotropy, a suitable elastic constant K33, a suitable and negative dielectric anisotropy, and an excellent compatibility with other liquid crystal compounds. The invention provides a liquid crystal composition containing the compound described above and having stability to heat, light and so forth, a small viscosity, a suitable optical anisotropy, a suitable and negative dielectric anisotropy, a suitable elastic constant K33, a low threshold voltage, a high maximum temperature of a nematic phase, and a low minimum temperature of the nematic phase. The invention also provides a liquid crystal display device having a short response time, a small power consumption, a low driving voltage, and a large contrast, and containing the composition described above which can be used in a large temperature range.
    Type: Grant
    Filed: September 1, 2008
    Date of Patent: November 12, 2013
    Assignees: JNC Corporation, JNC Petrochemical Corporation
    Inventors: Teru Shimada, Masahide Kobayashi
  • Patent number: 8580821
    Abstract: The present invention relates to trans-derivatives of formula wherein R1, R2, R3, and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: November 12, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christophe Grundschober, Patrick Schnider
  • Publication number: 20130281700
    Abstract: The invention relates to palladium(0)-tris{tri-[3,5-bis(trifluoromethyl)-phenyl]-phosphine} complex of formula (I), as well as to its preparation and use. This compound is outstandingly stable, and can be used as catalyst with excellent results.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 24, 2013
    Applicants: CHINOIN GYOGYSZER-ES VEGYESZETI TER-MEKEK GYARA ZRT, H4SEP KFT
    Inventors: Zoltán DALICZEK, Tibor SOÓS, Zoltán FINTA, Géza Timári, Gábor Vlád
  • Patent number: 8530665
    Abstract: The present invention provides crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5 -dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol useful in the treatment of cancer.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: September 10, 2013
    Assignee: Eli Lilly and Company
    Inventor: Benjamin Alan Diseroad
  • Patent number: 8530388
    Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: September 10, 2013
    Assignee: Syngenta Limited
    Inventors: William Guy Whittingham, Christopher John Mathews, Jeffrey Steven Wailes, Stephane André Marie Jeansmart, Louisa Robinson
  • Publication number: 20130228720
    Abstract: Chiral liquid crystal compounds of the general formula (1): in which at least one of R1 and R2 is a chiral substituent, K may be a single bond or the same as K1-5 and K1-5 denote a six-membered ring system which rings may be at least partially unsaturated, wherein the number of atoms in these rings or ring systems between the two atoms forming a part of the link to the next ring, or to one of the substituents R1 and R2, does not differ by more than one if counted in the clockwise, and in the counter-clockwise sense, starting from the same atom in each case, X1-20 denote alkyl, or alkoxy, or fluorinated alkyl, or fluorinated alkoxy groups, or atom H, or halogen atoms, mixtures comprising such chiral liquid crystal compounds, and liquid crystal displays comprising such mixtures as active ingredients
    Type: Application
    Filed: April 15, 2013
    Publication date: September 5, 2013
    Applicant: Tetragon LC Chemie AG
    Inventors: Wolfgang Haase, Artsiom Lapanik
  • Patent number: 8519144
    Abstract: A method is described for the preparation of aryl-pyridine compounds of formula (I) by cross-coupling reaction, promoted by catalytic systems based on palladium or nickel between compounds of formula (II) and (III) in which: -Met represents Mg or Zn, —Y represents Cl, Br, I or acetoxy, —Z represents I, Br, Cl, triflate, sulphonate, phosphate, —R1, R2, R3, R4, which are the same as one another or different, represent hydrogen, a linear and/or branched C1-C4 alkyl, and/or an aryl, and/or a heteroaryl, or R1 and R2 and/or R3 and R4, taken together, form a C3-C8 ring, an aryl and/or a heteroaryl, -A represents —COR5 where R5 represents hydrogen, a linear and/or branched C1-C4 alkyl, and/or an aryl, and/or a heteroaryl, or -A represents —CRs5(OR6)(OR7) where R5 has the meaning described above and R6 and R7, which are the same as one another or different, represent a linear and/or branched C1-C4 alkyl, and/or an aryl, and/or a heteroaryl, or R6 and R7, joined together, represent a C1-C8 alkyl or alkenyl.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: August 27, 2013
    Assignee: Euticals Prime European Therapeuticals SpA
    Inventors: Claudio Giordano, Luca Giannini
  • Patent number: 8507688
    Abstract: The present invention relates to a process for preparing ?-arylmethylcarbonyl compound of the formula (III), characterized in that aryl- and heteroarylacetic acids and derivatives thereof of the formula (I) are reacted with ?-halomethylcarbonyl compounds of the formula (II) in the presence of a palladium catalyst, of a phosphine ligand, of an inorganic base and of a phase transfer catalyst, optionally using an organic solvent.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: August 13, 2013
    Assignee: Bayer CropScience AG
    Inventors: Thomas Himmler, Lukas J. Gooβen, Bettina Zimmermann
  • Publication number: 20130203815
    Abstract: The present invention provides compounds represented by general formula (I): wherein, R1, R2, R3, L and T are as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, and prodrugs thereof. The invention also relates to processes for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful in the treatment of a condition or disorder mediated by one or more cytokines selected from Tumor Necrosis Factor-alpha (TNF-?) and interleukins such as IL-1, IL-6, and IL-8. The present invention further provides a method of treatment of inflammatory disorders by administering a therapeutically effective amount of the said compound of formula (I) or its pharmaceutical composition, to a mammal in need thereof.
    Type: Application
    Filed: March 25, 2011
    Publication date: August 8, 2013
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Babasaheb Pandurang Bandgar, Jalindar Vasant Totre
  • Publication number: 20130150409
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 13, 2013
    Applicant: AbbVie Inc.
    Inventor: AbbVie Inc.
  • Patent number: 8455656
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Publication number: 20130137869
    Abstract: There is described a non-planar iridium-ligand complex with accessible triplet states and a molecular structure that confers liquid-crystal like properties.
    Type: Application
    Filed: March 11, 2011
    Publication date: May 30, 2013
    Applicant: UNIVERSITY OF YORK
    Inventors: Duncan W. Bruce, Amedeo Santoro, Anton Mikhailovich Prokhorov
  • Patent number: 8440834
    Abstract: 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: May 14, 2013
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele Amari, Elisabetta Armani, Maurizio Delcanale
  • Publication number: 20130109713
    Abstract: The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Inventors: Edmond J. Lavoie, Ajit Parhi, Daniel S. Pilch
  • Publication number: 20130109708
    Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to 5 compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I):10 X NH O S O O R1 R2 R5 R4 R3 Het1 (I) or a pharmaceutically acceptable salt thereof, wherein X, Het1, R1, R2, R3, R4 and R5 are as defined in the description. 15 Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
    Type: Application
    Filed: July 4, 2011
    Publication date: May 2, 2013
    Applicant: Pfizer Limited
    Inventors: Alan Daniel Brown, David James Rawson, Robert Ian Storer, Nigel Alan Swain
  • Patent number: 8372975
    Abstract: The invention provides a liquid crystal compound having general physical properties necessary for the compound, namely stability to heat, light and so forth, a wide temperature range of a liquid crystal phase, a high clearing point, a good compatibility with other compounds, a large optical anisotropy and a large dielectric anisotropy; a compound represented by formula (1): wherein, for example, R1 is alkyl having 1 to 20 carbons; ring A1 and ring A4 each are 1,4-cyclohexylene, 1,4-phenylene, or 1,4-phenylene in which arbitrary hydrogen is replaced by halogen; Z1 and Z4 each are a single bond; L1, L2, L3 and L4 each are hydrogen or fluorine; and X1 is fluorine, chlorine, —CF3 or —OCF3.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: February 12, 2013
    Assignees: JNC Corporation, JNC Petrochemical Corporation
    Inventor: Hiroyuki Tanaka
  • Patent number: 8367838
    Abstract: The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: February 5, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Kolczewski, Hans-Peter Marty, Robert Narquizian, Emmanuel Pinard, Henri Stalder
  • Patent number: 8344152
    Abstract: The present invention relates to a process for producing a pyridylethylthio compound which is improved in yield of the pyridylethylthio compound. In a process for producing a pyridylethylthio compound by reacting vinyl pyridine with a sulfur-containing compound, vinyl pyridine used contains a compound represented by the general formula (1): (wherein R1 and R2 are any of combination of isopropenyl group and a hydrogen atom, combination of 1-propenyl group and a hydrogen atom, combination of 2-propenyl group and a hydrogen atom, and combination of methyl group and vinyl group), in an amount of not more than 4% by weight.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: January 1, 2013
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Hideto Hayashi, Koichi Hayashi
  • Patent number: 8338602
    Abstract: Quaternary nitrogen heterocyclic boronic acid-containing compounds are described, which are sensitive to glucose and fructose, as well as a variety of other physiologically important analytes, such as aqueous chloride and iodide, and a method of using the compounds. Also disclosed is a contact lens doped with the quaternary nitrogen heterocyclic boronic acid-containing compound, and a method of using the doped contact lens to measure the concentration of analyte in tears under physiological conditions.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: December 25, 2012
    Assignee: University of Maryland, Baltimore County
    Inventors: Chris D. Geddes, Ramachandram Badugu, Joseph R. Lakowicz
  • Patent number: 8338553
    Abstract: Disclosed are a solvatochromic functional monomer having the chemical structure and a process for preparing the same. The solvatochromic functional monomer can be used for fabrication of molecularly imprinted polymer based (MIP-based) solvatochromic chemosensors. This involves the incorporation of the solvatochromic functional monomer as reporter into the molecularly imprinted polymer. The solvatochromic functional monomers as reporters signal the analyte-to-receptor displacing event within the receptor sites without the need for intermolecular interaction between the analyte and the receptor.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: December 25, 2012
    Assignee: City University of Hong Kong
    Inventors: Hon-Wah Lam, Chengbin Gong